The abstract is read at the publisher; the summary is JClub's.
One intravenous dose of VERVE-102 in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease reduced liver PCSK9 protein dose-dependently, reaching an 88% mean reduction at 1.0 mg/kg.
- Why it matters: Loss-of-function PCSK9 variants are linked to lower LDL cholesterol and fewer atherosclerotic cardiovascular events, but durable inactivation in the liver needs safer, targeted approaches.
- What they did: In a phase 1 open-label single-ascending-dose study, participants received one VERVE-102 infusion (0.3–1.0 mg total RNA per kilogram) and investigators measured blood PCSK9 protein and LDL cholesterol over follow-up.
- The result: PCSK9 reductions of 51% to 88% corresponded to LDL cholesterol decreases from 9% to 62%, including an absolute 78 mg/dL drop at 1.0 mg/kg, with durability through at least 1 year in 15 participants.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
- Open access